Bladder cancer became a VA presumptive condition through two separate regulatory pathways — a distinction that matters because each pathway has different eligibility requirements and different effective date implications.
On September 2, 2021, VA published a final rule adding bladder cancer to the list of diseases presumptively associated with herbicide agent exposure under 38 CFR § 3.309(e). This expansion was driven by findings from the National Academies of Sciences report on Veterans and Agent Orange, which found sufficient or at least limited/suggestive evidence linking herbicide exposure to bladder cancer.
The Agent Orange presumptive applies to veterans who served in:
The PACT Act of 2022 added bladder cancer to VA's expanded presumptive list for veterans with qualifying toxic exposures at covered locations. This pathway covers veterans who:
For PACT Act claims, veterans do not need to individually prove they were exposed to a specific chemical — the deployment location itself creates the qualifying exposure presumption.
If you served in Vietnam and have bladder cancer, claim under 38 CFR § 3.309(e) (Agent Orange). If you served in Southwest Asia after 1990, claim under the PACT Act. If you served in both eras, you qualify under both — use whichever provides the earliest effective date. Your VA-accredited attorney or VSO can help you select the optimal pathway.
Eligibility for the bladder cancer presumptive is based entirely on your service history — not on proving that your specific exposure caused your specific cancer. You must meet three criteria:
Veterans do not need to prove any specific exposure event. If you set foot in Vietnam, walked on a covered base in Thailand, or deployed to Iraq or Afghanistan, the presumption applies. The burden is on VA to disprove service connection, not on the veteran to prove it.
VA rates bladder cancer under Diagnostic Code 7528 in 38 CFR Part 4. DC 7528 covers "malignant neoplasms of the genitourinary system" and follows VA's general malignant neoplasm rating framework.
| Condition Phase | Rating | Regulatory Basis |
|---|---|---|
| Active bladder cancer (during treatment) | 100% | DC 7528; 38 CFR § 4.115a |
| Six-month post-treatment evaluation period | 100% | 38 CFR § 3.105(e) minimum continuance |
| Residual urinary dysfunction — after evaluation | 10–60% | DC 7518 (urinary tract) or DC 7517 (bladder) |
| Incontinence requiring absorbent products | 10–40% | DC 7542 (urinary incontinence) |
The rating structure for bladder cancer creates two distinct phases: the active cancer/treatment phase (always 100%) and the residual phase (rated based on functional impairment). Veterans often make the mistake of thinking their claim is "over" after treatment. It is not — the residuals phase can result in ratings of 10–60% that are permanent if functional impairment remains.
Under VA's malignant neoplasm rating policy, any active malignant cancer is rated at 100% for the duration of treatment. "Active treatment" includes surgery (cystectomy, TURBT), intravesical chemotherapy (BCG therapy), systemic chemotherapy, and radiation therapy.
The 100% rating during treatment reflects VA's recognition that cancer treatment is itself disabling — it prevents work, causes fatigue, nausea, pain, and functional impairment that goes well beyond the underlying tumor itself.
The effective date for your 100% rating is the date VA receives your claim. If you wait three months after your bladder cancer diagnosis before filing, you lose three months of 100% back pay — potentially $10,000–$11,000 or more. File immediately upon diagnosis, even if you don't have all your records yet. You can supplement the record later; the filing date is locked in when you first submit.
VA considers the following as active treatment for rating purposes:
For veterans on maintenance BCG therapy or surveillance cystoscopy schedules, the question of when "active treatment" ends becomes important. VA guidance generally treats ongoing BCG maintenance as active treatment, but this can be disputed at C&P exams. Document your complete treatment plan and active therapy schedule carefully.
Six months after treatment cessation, VA will schedule a re-evaluation C&P exam to determine a residual rating. This is one of the most important — and most frequently mishandled — phases of a bladder cancer claim.
Residual conditions from bladder cancer and its treatment can include:
Veterans who undergo radical cystectomy (bladder removal) will have urinary diversion — either a neobladder (internal reservoir using bowel segment), ileal conduit (external bag), or continent pouch. The rating for urinary diversion is typically high because voiding function is permanently altered:
Veterans who retain their bladder but undergo TURBT and BCG therapy often experience persistent urinary frequency, urgency, incontinence, and hematuria. These are rated under:
| Urinary Frequency Rating | Criteria |
|---|---|
| 10% | Daytime voiding 4–6 times per day, or awakening 2 times per night |
| 20% | Daytime voiding 7–10 times, or awakening 3 times per night |
| 40% | Daytime voiding 11+ times, or awakening 4+ times per night |
Radical cystectomy and pelvic radiation frequently cause erectile dysfunction in male veterans and sexual dysfunction in female veterans. These secondary conditions are separately ratable under DC 7522 (erectile dysfunction) or the appropriate female reproductive codes. VA does not automatically add these — you must claim them.
Many bladder cancer veterans leave significant benefits unclaimed because they don't know to file for conditions caused or aggravated by their service-connected bladder cancer or its treatment. Secondary conditions to consider claiming:
Filing a bladder cancer presumptive claim follows the same general process as other VA disability claims, with a few specific considerations:
List your condition as "Bladder cancer — presumptive under 38 CFR § 3.309(e) due to Agent Orange exposure during Vietnam service" (for Vietnam vets) or "Bladder cancer — PACT Act presumptive due to burn pit/toxic exposure during service in [location] [dates]" (for post-9/11 vets). This ensures the claim is routed to the correct adjudication pathway immediately.
For the full details on the PACT Act genitourinary cancer presumptives (including kidney, ureter, and testicular cancer), see our comprehensive guide: PACT Act Genitourinary Cancer VA Claims.
If you were denied bladder cancer service connection before September 2021 (Agent Orange expansion) or before August 2022 (PACT Act effective date), your denial may now be overturnable.
Options for reopening a previously denied bladder cancer claim:
VA estimated that approximately 35,000 veterans would become newly eligible for benefits following the 2021 Agent Orange expansion that added bladder cancer, hypothyroidism, and other conditions. If you or a family member had a bladder cancer claim denied before 2021, reopening is straightforward and urgent — there are retroactive payment implications.
Your C&P exam is where VA evaluates the severity of your current bladder cancer condition and any residual disabilities. Being well-prepared significantly affects your rating:
Find Out If You Qualify
Bladder cancer is presumptive for Agent Orange and PACT Act veterans. Our free claim review connects you with VA-accredited attorneys who handle cancer claims and can help maximize your rating from diagnosis through residuals.
Check My Bladder Cancer Claim →Editorial Standards: Written by Marcus J. Webb, veterans benefits researcher. Verified against 38 CFR § 3.309(e), DC 7528, and PACT Act provisions. Last reviewed: July 2026. Not legal advice — for representation, connect with a VA-accredited attorney.
Bladder cancer is presumptive — no nexus letter required. Don't delay; your effective date starts when you file.
Start My Free Claim Review — No Phone Required →